Philips grows cardiac monitoring business with Cardiologs pickup

Nearly one year after announcing its $2.8 billion acquisition of BioTelemetry, the Dutch conglomerate is further expanding its reach in remote patient monitoring with the purchase of France-based Cardiologs.

By Susan Kelly • Nov. 9, 2021

Robotics startup Vicarious files pre-submission with FDA, fresh from $220M SPAC raise

The filing is part of a push to establish the robotic surgical system in a space fought over by Intuitive Surgical, Johnson & Johnson and Medtronic.

By Nick Paul Taylor • Nov. 9, 2021

Explore the Trendline➔

Medical device industry continues to turn to AI

While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.

By MedTech Dive staff

Latest Abbott, Boston Scientific LAAC devices yield mixed results in first clinical comparison

No clear difference was evident in clinical outcomes at 45 days, but other endpoints did point toward potential pros and cons of the two left atrial appendage closure devices.

By Nick Paul Taylor • Nov. 8, 2021

Edwards, Medtronic bolster economic, clinical case for using TAVR over surgery

Medtronic released five-year data from the SURTAVI trial while Edwards presented a two-year study of the costs of TAVR and surgery, both of which were late-breaking clinical trials at the TCT annual scientific symposium.

By Nick Paul Taylor • Nov. 8, 2021

iRhythm's COVID-19 pressures add to Medicare pricing saga

New CEO Quentin Blackford told investors "significant" customer staffing issues are likely to drag on through Q4, limiting the company's capacity and forcing it to lower 2021 guidance.

By Ricky Zipp • Nov. 5, 2021

Stryker, Zimmer, Smith & Nephew warn orthopaedic headwinds to last into Q4

Third-quarter results reveal how the industry remains constrained by COVID-19, hospital staffing shortages and lower pricing in China. 

By Nick Paul Taylor • Nov. 5, 2021

FDA issues long-awaited draft software guidance in overhaul of 16-year-old policy

The proposal applies to all types of premarket submissions and includes both software in and Software as a Medical Device.

By Nick Paul Taylor • Nov. 4, 2021

Why are women more likely to use telehealth?

As Washington mulls over telehealth regulations post-COVID-19, it's important not to roll back access in a way that could disproportionately affect women, experts say.

By Rebecca Pifer • Nov. 3, 2021

CMS finalizes plans for pay cuts for radiation oncology, other specialists

Device makers could feel the pinch in cuts to services that use pricey equipment for vascular surgery, interventional radiology and diagnostic testing, which AdvaMed contends will decrease patient access to care.

By Shannon Muchmore • Nov. 3, 2021

CMS reinstates Medicare's inpatient-only list in final rule, reversing Trump-era nix

Medtronic, Johnson & Johnson, Stryker and Zimmer Biomet overwhelmingly supported restoring the IPO list in public comments to the July proposed rule. The backing comes as the industry also embraces outpatient care.

By Ricky Zipp • Nov. 3, 2021

Outset nabs first CMS home dialysis add-on payment, setting up fight with Fresenius

The company, whose application was rejected last year, persuaded the Medicare agency its portable dialysis machine is a "substantial clinical improvement" over the incumbent home-use hemodialysis product.

By Nick Paul Taylor • Nov. 3, 2021

Safety of Endologix endovascular graft device center of FDA panel review

The medtech competes in a space targeted by companies including Cook Medical and Medtronic. Agency advisers will discuss the broader endovascular graft market Wednesday.

By Nick Paul Taylor • Nov. 2, 2021

Siemens' Varian leads latest FDA breakthrough device designations

Varian secured the regulatory privileges for its noninvasive treatment of knee osteoarthritis based on technology acquired from Boston Scientific. Magnus Medical, Renovia and MY01 are included in the latest batch of designations.

By Nick Paul Taylor • Nov. 1, 2021

With remote collaboration technology, busy device representatives can "be there" for diverse accounts across growing territories

Silicon Valley- based technology company, Avail Medsystems, offers an all-encompassing remote collaboration platform technology so device representatives can be in the room for procedures even when they can’t be there.

Nov. 1, 2021

3 trends dragging medtechs: Supply chain constraints, inflation and hospital staffing shortages

J&J, ResMed and Stryker are among the companies citing one of these factors as constraining growth in the current reporting season.

By Nick Paul Taylor • Nov. 1, 2021

FDA, global peers create guiding principles for AI/ML medical devices

The U.S., U.K. and Canada are seeking international harmonization as part of a broader discussion on the development of safe, effective devices that use artificial intelligence and machine learning.

By Nick Paul Taylor • Oct. 29, 2021

What does J&J's Ottava delay mean for Intuitive and Medtronic? It's complicated.

The setback doesn't remove hurdles the rivals face playing catch-up to market leader Intuitive's da Vinci, which has a two-decade head start. 

By Ricky Zipp • Oct. 28, 2021

FDA restricts breast implant sales, cites Allergan and J&J for inadequate postapproval progress

The agency also made official a boxed warning, after an advisory panel heard from dozens of patients with a cancer associated with breast implants and symptoms of a related illness.

By Nick Paul Taylor • Oct. 28, 2021

Edwards TAVR volumes tepid in October, quashing hopes of fast recovery from delta

"We didn't want to send a signal that all of a sudden October is back to the kind of thing that we were experiencing in Q2. We're not experiencing that kind of an environment yet," CEO Mike Mussallem told investors Wednesday.

By Nick Paul Taylor • Oct. 28, 2021

Boston Scientific CEO projects better Q4 and 2022 as delta surge wanes

Michael Mahoney was optimistic that procedure volumes will rebound as the variant subsides and vaccination rates rise. However, the CEO acknowledged pressure from a "spotty" COVID-19 recovery and hospital staffing shortages.

By Ricky Zipp • Oct. 27, 2021

FDA's 2022 A-list guidance plan hits on software, post-pandemic future

The agency's priorities include a much-anticipated final guidance on clinical decision support software — more than five years in the making — meant to clarify when CDS meets the definition of a medical device.

By Nick Paul Taylor • Oct. 27, 2021

Like 'Whac-A-Mole': GE Healthcare says supply chain woes to last into 2022

"I'm not sure we're yet in a place where we would say that things are stable," GE CEO Larry Culp told investors Tuesday. The healthcare unit took the biggest hit among the conglomerate's business lines due to delays.

By Greg Slabodkin • Oct. 26, 2021

Notified bodies join chorus of criticism of proposed European AI regs

Team-NB has come out strongly against the regulation, arguing it will add to administrative burdens, reduce notified body capacity and create confusion.

By Nick Paul Taylor • Oct. 26, 2021

Zimmer, J&J chase Stryker's lead in ortho robotics

"I don't think it's a market share battle as much as market expansion. All the companies are riding this wave," said Needham & Co. analyst Mike Matson.

By Susan Kelly • Oct. 25, 2021

Roche's refillable eye implant becomes Eylea's latest threat

The FDA has approved Susvimo, a device that continuously administers a version of Roche's Lucentis over several months. It could challenge Regeneron's top-selling drug.

By Ben Fidler • Oct. 25, 2021